Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:ITRMNASDAQ:LABPNASDAQ:NRSN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.05+0.7%$0.05$0.03▼$11.15$667K0.6760,509 shs135 shsITRMIterum Therapeutics$1.52-1.7%$1.51$0.62▼$2.50$25.03M2.36501,265 shs18,007 shsLABPLandos Biopharma$22.30+0.5%$13.40$2.50▼$22.84$69.58M0.1421,817 shs2,940 shsNRSNNeuroSense Therapeutics$1.27-5.1%$1.65$0.40▼$2.33$17.38M1.58275,037 shs45,959 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics-7.68%-0.73%-9.68%-6.72%-99.25%ITRMIterum Therapeutics-1.90%+7.64%0.00%-6.63%+51.22%LABPLandos Biopharma+0.95%+3.18%+4.44%+367.78%+671.03%NRSNNeuroSense Therapeutics-1.47%-16.25%-26.37%+30.10%-36.79%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1198 of 5 stars3.00.00.04.83.20.00.6ITRMIterum Therapeutics0.8763 of 5 stars3.52.00.00.00.60.00.6LABPLandos Biopharma0.1252 of 5 stars1.03.00.00.00.60.80.6NRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,569.72% UpsideITRMIterum Therapeutics3.00Buy$6.00293.86% UpsideLABPLandos Biopharma2.00Hold$20.42-8.43% DownsideNRSNNeuroSense Therapeutics3.00BuyN/AN/ACurrent Analyst RatingsLatest BLPH, ITRM, LABP, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.004/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/ALABPLandos Biopharma$18M3.87N/AN/A$10.20 per share2.19NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)NRSNNeuroSense Therapeutics-$11.28M-$0.83N/A∞N/AN/A-678.59%-207.30%6/6/2024 (Estimated)Latest BLPH, ITRM, LABP, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96ITRMIterum Therapeutics3.631.891.89LABPLandos BiopharmaN/A6.096.09NRSNNeuroSense TherapeuticsN/A0.840.84OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%ITRMIterum Therapeutics9.21%LABPLandos Biopharma49.06%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%ITRMIterum Therapeutics5.40%LABPLandos Biopharma1.30%NRSNNeuroSense Therapeutics27.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableNRSNNeuroSense Therapeutics1413.67 million9.92 millionNot OptionableBLPH, ITRM, LABP, and NRSN HeadlinesSourceHeadlineNeuroSense Therapeutics (NASDAQ:NRSN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) Head-To-Head Comparisonamericanbankingnews.com - April 23 at 1:24 AMNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Diseasefinance.yahoo.com - April 22 at 8:41 AMNeuroSense reports positive ALS trial results, trends in biomarkersinvesting.com - April 19 at 11:23 PMNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meetingprnewswire.com - April 18 at 8:30 AMNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024finance.yahoo.com - April 12 at 10:35 AMNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024prnewswire.com - April 12 at 8:30 AMNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placementprnewswire.com - April 10 at 7:16 PMNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketmarkets.businessinsider.com - April 9 at 12:36 PMNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnosticsprnewswire.com - April 9 at 8:30 AMNeuroSense reports significant ALS trial results, year-end financialsuk.investing.com - April 7 at 7:25 PMNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023investorplace.com - April 5 at 9:01 PMNeuroSense Announces Year End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - April 5 at 1:16 PMNeuroSense Therapeutics Ltd NRSNmorningstar.com - March 23 at 12:06 AMNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trialfinance.yahoo.com - February 21 at 1:22 PMNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trialprnewswire.com - February 21 at 8:30 AMNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rulefinance.yahoo.com - February 7 at 1:25 PMNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024finanznachrichten.de - January 30 at 7:17 PMNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024finance.yahoo.com - January 30 at 8:44 AMNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalystsfinance.yahoo.com - January 9 at 12:36 PMNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirementfinance.yahoo.com - January 4 at 1:25 AMNeurosense Therapeutics (NRSN) Earnings Dates & Reportsinvesting.com - December 19 at 1:36 PMAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)markets.businessinsider.com - December 16 at 12:59 AMNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trialfinance.yahoo.com - December 14 at 1:38 PMAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)markets.businessinsider.com - December 8 at 4:27 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.NeuroSense TherapeuticsNASDAQ:NRSNNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.